Table 4.

Outcomes of interest in intent-to-treat population compared to Sunitinib before and after meta-regression (shown as hazard ratio and 95% credible intervals).

Outcomes	Methods	Cabo	PemAxi	AveAxi	LenPem	NivoCabo	LenEvero
PFS	meta-analysis	2.08(1.12,3.87)	1.46(1.01,2.19)	1.82(1.10,3.02)	2.56(1.55,4.24)	1.79(1.09,2.94)	×
	meta-regression analysis	2.30(1.10,4.60)	×	2.10(1.02,4.40)	2.50(1.50,4.30)	×	×
OS	meta-analysis	×	2.08(1.07,4.03)	1.93(1.04,3.56)	2.27(1.28,4.03)	×	×
	meta-regression analysis	×	2.00(1.81,4.30)	×	1.90(1.30,4.50)	×	×
ORR	meta-analysis	4.01(1.44,11.40)	2.28(1.35,3.80)	2.98(1.57,5.54)	4.36(2.28,8.18)	3.19(1.68,6.16)	2.04(1.07,3.82)
	meta-regression analysis	3.80(1.10,12.00)	2.20(1.04,4.90)	×	4.30(2.10,8.90)	3.10(1.02,9.90)	2.00(1.08,4.10)
AE	meta-analysis	×	×	-	2.07 (1.46,2.93)	×	2.20 (1.55,3.14)
	meta-regression analysis	×	×	-	×	×	×

PemAxi, Pembrolizumab plus Axitinib; AveAxi, Avelumab plus Axitinib; LenPem, Lenvatinib plus Pembrolizumab; NivoCabo, Nivolumab plus Cabozantinib; LenEvero, Lenvatinib plus Everolimus; Cabo, Cabozantinib.

×: the treatment on the top is not significant compared to Sunitinib.